Keyword Analysis & Research: checkmate 816

nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2202170

WebApr 11, 2022 · CheckMate 816 builds on robust findings for nivolumab-based regimens in advanced NSCLC 12-14 and a strong biologic rationale for use in resectable NSCLC, …

DA: 37 PA: 91 MOZ Rank: 83

fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung

WebMar 4, 2022 · Efficacy was evaluated in CHECKMATE-816 (NCT02998528), a randomized, open label trial in patients with resectable, histologically confirmed Stage IB (≥4 cm), II, …

DA: 28 PA: 62 MOZ Rank: 56

ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.TPS8577

WebMay 30, 2017 · Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage … Author: Patrick M. Forde, Jamie E. Chaft, Enriqueta Felip, Stephen Broderick, Nicolas Girard, Mark M. Awad, ... Publish Year: 2017

Author: Patrick M. Forde, Jamie E. Chaft, Enriqueta Felip, Stephen Broderick, Nicolas Girard, Mark M. Awad, ...

Publish Year: 2017

DA: 80 PA: 33 MOZ Rank: 82

ascopubs.org

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.8503

WebMay 28, 2021 · Background: CheckMate 816 (NCT02998528) is a randomized phase 3 study of neoadjuvant NIVO + chemo vs chemo in resectable NSCLC. The study met its … Author: Jonathan Spicer, Changli Wang, Fumihiro Tanaka, Gene Brian Saylors, Ke-Neng Chen, Moishe Liberman, E... Publish Year: 2021

Author: Jonathan Spicer, Changli Wang, Fumihiro Tanaka, Gene Brian Saylors, Ke-Neng Chen, Moishe Liberman, E...

Publish Year: 2021

DA: 38 PA: 40 MOZ Rank: 45

nih.gov

https://pubmed.ncbi.nlm.nih.gov/35403841/

WebMay 26, 2022 · The addition of nivolumab to neoadjuvant chemotherapy did not increase the incidence of adverse events or impede the feasibility of surgery. (Funded by Bristol …

DA: 20 PA: 65 MOZ Rank: 95

cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2022/nivolumab-chemotherapy-neoadjuvant-lung-cancer

WebMay 20, 2022 · In the CheckMate 816 trial, people with early-stage non-small cell lung cancer (stage IB to IIIA) received either nivolumab (Opdivo) and chemotherapy or …

DA: 91 PA: 55 MOZ Rank: 30

ascopubs.org

https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS8577

WebMay 30, 2017 · Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage …

DA: 33 PA: 81 MOZ Rank: 40

nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMc2208133

WebMay 26, 2022 · To the Editor: In the CheckMate 816 trial, Forde and colleagues (May 26 issue) 1 concluded that neoadjuvant treatment with nivolumab did not impede the …

DA: 23 PA: 65 MOZ Rank: 53

clinicaltrials.gov

https://clinicaltrials.gov/ct2/show/NCT02998528

WebDec 20, 2016 · A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer …

DA: 18 PA: 28 MOZ Rank: 27

obroncology.com

https://www.obroncology.com/conference-news/groundbreaking-checkmate-816-trial-that-led-to-fda-approval-presented

WebApr 12, 2022 · Groundbreaking CHECKMATE-816 Trial that Led to FDA Approval Presented. Nivolumab plus chemotherapy as a neoadjuvant treatment improves event …

DA: 59 PA: 15 MOZ Rank: 76